These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21047568)

  • 21. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).
    Hedblad B; Wikstrand J; Janzon L; Wedel H; Berglund G
    Circulation; 2001 Apr; 103(13):1721-6. PubMed ID: 11282901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 1-year treatment with fluvastatin or pravastatin on bone.
    Watanabe S; Fukumoto S; Takeuchi Y; Fujita H; Nakano T; Fujita T
    Am J Med; 2001 May; 110(7):584-7. PubMed ID: 11343673
    [No Abstract]   [Full Text] [Related]  

  • 24. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
    Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
    BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.
    Thiébaud D; Sauty A; Burckhardt P; Leuenberger P; Sitzler L; Green JR; Kandra A; Zieschang J; Ibarra de Palacios P
    Calcif Tissue Int; 1997 Nov; 61(5):386-92. PubMed ID: 9351880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
    Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
    Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption.
    Giusti A; Camellino D; Saverino D; Iervasi E; Girasole G; Bianchi G; Papapoulos SE
    Bone; 2020 Sep; 138():115512. PubMed ID: 32603908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
    Hue TF; Cummings SR; Cauley JA; Bauer DC; Ensrud KE; Barrett-Connor E; Black DM
    JAMA Intern Med; 2014 Oct; 174(10):1550-7. PubMed ID: 25111880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
    Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
    Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
    Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluvastatin.
    Lawrence JM; Reckless JP
    Expert Opin Pharmacother; 2002 Nov; 3(11):1631-41. PubMed ID: 12437496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P; Gamerdinger D; Spieler W; Kann PH; Loeffler H; Articus K; Möricke R; Ziller V
    Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM.
    Nishimura S; Mishra-Gorur K; Park J; Surovtseva YV; Sebti SM; Levchenko A; Louvi A; Gunel M
    Proc Natl Acad Sci U S A; 2017 May; 114(21):5503-5508. PubMed ID: 28500274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.
    Wark JD; Bensen W; Recknor C; Ryabitseva O; Chiodo J; Mesenbrink P; de Villiers TJ
    Osteoporos Int; 2012 Feb; 23(2):503-12. PubMed ID: 21331467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.